Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline for prevention of delayed cerebral ischaemia after aneurysmal subarachnoid haemorrhage
ACTRN12618001932257Phase 2Not yet recruiting
- Sponsor
- John Hunter Hospital
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in subarachnoid hemorrhage (SAH) and delayed cerebral ischemia (DCI) comparing Pentoxifylline with Placebo (2 arms). Primary endpoint: Incidence of delayed cerebral ischaemia. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
pentoxifylline
03
Conditions
subarachnoid hemorrhage (SAH)delayed cerebral ischemia (DCI)
Beyond the preview
Go deeper on ACTRN12618001932257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618001932257.